N-(4-tert-butyl-phenyl)-4-(3-cyclopentylamino-pyridin-2-yl)-benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-tert-butyl-phenyl)-4-(3-cyclopentylamino-pyridin-2-yl)-benzamide
• 英文别名: N-(4-tert-butylphenyl)-4-(3-(cyclopentylamino)pyridin-2-yl)benzamide；N-(4-tert-butylphenyl)-4-[3-(cyclopentylamino)pyridin-2-yl]benzamide
• 化学式: C₂₇H₃₁N₃O
• 分子量: 413.563
• InChiKey: BLSWNJAPQMAPOE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  54
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-羧基苯硼酸 在 四(三苯基膦)钯 、 三乙酰氧基硼氢化钠 、 sodium carbonate 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 溶剂黄146 、 tin(ll) chloride 作用下， 以 乙二醇二甲醚 、 二氯甲烷 、 乙酸乙酯 、 1,2-二氯乙烷 为溶剂， 反应 2.0h， 生成 N-(4-tert-butyl-phenyl)-4-(3-cyclopentylamino-pyridin-2-yl)-benzamide
  参考文献：
  名称：

  从芳基脲到联芳基酰胺再到氨基喹唑啉：发现新型有效的TRPV1拮抗剂。

  摘要：

  铅VR1拮抗剂1中芳基环的哌嗪生物等位取代导致了联芳基酰胺系列的产生。B环SAR的发展导致构象受限的类似物70。所得氨基喹唑啉70代表一种新型VR1拮抗剂，与先导系列的类似化合物相比，具有更高的体外效价和口服生物利用度。

  DOI：

  10.1016/j.bmcl.2006.07.010

文献信息

• Substituted biphenyl-4-carboxylic acid arylamide analogues
  申请人：Bakthavatchalam Rajagopal

  公开号：US20060100245A1

  公开（公告）日：2006-05-11

  Substituted biphenyl-4-carboxylic acid arylamide analogues capable of modulating receptor activity, are provided. Such ligands may be used to modulate receptor activity in vivo or in vitro, and are particularly useful in the treatment of pain and other conditions associated with receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for receptor localization studies.

  提供了能够调节受体活性的取代联苯-4-羧酸芳香酰胺类似物。这样的配体可以用于体内或体外调节受体活性，并且在治疗与人类、家畜伴侣动物和家畜动物中的受体激活有关的疼痛和其他疾病方面特别有用。提供了用于治疗此类疾病的制药组合物和方法，以及用于受体定位研究的配体使用方法。
• SUBSTITUTED BIARYL-4-CARBOXYLIC ACID ARYLAMIDE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS
  申请人：NEUROGEN CORPORATION

  公开号：EP1575918A2

  公开（公告）日：2005-09-21
• [EN] SUBSTITUTED BIPHENYL-4-CARBOXYLIC ACID ARYLAMIDE ANALOGUES<br/>[FR] ANALOGUES D'ARYLAMIDE D'ACIDE BIPHENYL-4-CARBOXYLIQUE SUBSTITUES
  申请人：NEUROGEN CORP

  公开号：WO2004056774A2

  公开（公告）日：2004-07-08

  Substituted biphenyl-4-carboxylic acid arylamide analogues of the formula (I) capable of modulating receptor activity, are provided. Such ligands may be used to modulate receptor activity in vivo or in vitro, and are particularly useful in the treatment of pain and other conditions associated with receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for receptor localization studies.
• From arylureas to biarylamides to aminoquinazolines: Discovery of a novel, potent TRPV1 antagonist
  作者：Xiaozhang Zheng、Kevin J. Hodgetts、Harry Brielmann、Alan Hutchison、Frank Burkamp、A. Brian Jones、Peter Blurton、Robert Clarkson、Jayaraman Chandrasekhar、Rajagopal Bakthavatchalam、Stéphane De Lombaert、Marci Crandall、Daniel Cortright、Charles A. Blum

  DOI：10.1016/j.bmcl.2006.07.010

  日期：2006.10

  Bioisosteric replacement of piperazine with an aryl ring in lead VR1 antagonist 1 led to the biarylamide series. The development of B-ring SAR led to the conformationally constrained analog 70. The resulting aminoquinazoline 70 represents a novel VR1 antagonist with improved in vitro potency and oral bioavailability vs the analogous compounds from the lead series.

  铅VR1拮抗剂1中芳基环的哌嗪生物等位取代导致了联芳基酰胺系列的产生。B环SAR的发展导致构象受限的类似物70。所得氨基喹唑啉70代表一种新型VR1拮抗剂，与先导系列的类似化合物相比，具有更高的体外效价和口服生物利用度。